Wells Fargo’s Alder Biopharmaceuticals ALDR Stock Holding History

Wells Fargo’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-128,300	Closed	-$19K	–	7042
2019 Q3	$19K	Buy	128,300 +96,800	+307%	+$1.11M	﹤0.01%	5824
2019 Q2	$103K	Buy	+31,500	New	+$381K	﹤0.01%	5295
2019 Q1	–	Sell	-31,500	Closed	-$162K	–	6678
2018 Q4	$162K	Buy	+31,500	New	+$403K	﹤0.01%	5054

Wells Fargo's ALDR Position: Q4 2019 in Review

Wells Fargo sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 304,963 shares — an estimated $5.75M sold.

Wells Fargo first reported a position in ALDR in Q2 2014 and held it in 22 quarters. The position peaked at $14M in Q2 2016. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

Wells Fargo reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
Wells Fargo sold 304,963 Alder Biopharmaceuticals shares in Q4 2019, an estimated $5.75M.
Wells Fargo first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 22 quarters.
Wells Fargo's Alder Biopharmaceuticals position peaked at $14M in Q2 2016.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Wells Fargo's 13F filing for Q4 2019, filed 14 Feb 2020.